FDA Seeking Input On Long-Term Follow-Up For HIV Entry Inhibitors
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA and the Forum for Collaborative HIV Research will hold a public meeting on Jan. 18 to discuss the appropriate collection of long-term follow-up data for CCR5 antagonist clinical trials.
You may also be interested in...
Review Of Pfizer’s Maraviroc Will Reflect CCR5 Antagonist Class Safety Issues
FDA’s Antiviral Drugs Advisory Committee will also assess whether existing data supports accelerated approval for the first-in-class HIV therapy.
Review Of Pfizer’s Maraviroc Will Reflect CCR5 Antagonist Class Safety Issues
FDA’s Antiviral Drugs Advisory Committee will also assess whether existing data supports accelerated approval for the first-in-class HIV therapy.
CCR5 Antagonist Development Meeting Postponed
FDA and the Forum for Collaborative HIV Research have postponed a meeting to discuss CCR5 antagonist development until February or March in order to analyze new data